A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain

Authors


David C. Henderson, Freedom Trail Clinic, 25 Staniford Street, Boston, MA 02114, USA.
E-mail: dchenderson@partners.org

Abstract

Objective:  This study sought to examine the effectiveness of sibutramine, a weight loss agent, on clozapine-associated weight gain.

Method:  This was a 12-week double-blind, placebo controlled, randomized trial of sibutramine for weight loss in obese clozapine-treated schizophrenia or schizoaffective disorder subjects.

Results:  Ten patients were enrolled into the placebo group and 11 patients into the sibutramine group. There were no significant baseline differences between the two groups on age, gender, education, ethnicity, diagnosis, weight, body mass index (BMI), and blood pressure. At week 12, there were no significant differences in changes in weight, BMI, abdominal and waist circumferences, Hba1c, fasting glucose, or cholesterol levels.

Conclusion:  Sibutramine treatment did not show significant weight loss compared with placebo in clozapine-treated patients with schizophrenia or schizoaffective disorder. Further research with a larger sample size and longer follow-up duration is warranted.

Ancillary